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Genetic polymorphisms of the serotonin transporter, but not the
2a receptor or nitric oxide synthetase, are associated with
pulmonary hypertension in chronic obstructive pulmonary
disease
Abstract
Background: Pulmonary hypertension (PH) is prognosti- cally important in chronic obstructive
pulmonary disease (COPD). Since PH only weakly correlates with hypoxemia, other factors must play a
role. Objective: To investigate whether polymorphisms of the serotonin transporter (5HTT),
serotonin-2a receptor (5HTR2a) and endothelial nitric oxide synthetase (eNOS) are related to PH in
COPD. Methods: In 59 COPD patients who underwent right heart catheterization, 6-min walking
distance, NYHA functional class, pulmonary function tests, blood gases and 5HTT, 5HTR2a and eNOS
(4ab and T298C) polymorphisms were determined. Results: Forty-nine COPD patients in NYHA
functional class III-IV were included. Ten were excluded due to comorbid causes of PH (mainly chronic
thromboembolic). PH (mPAP ge25 mm Hg) was present in 55% and usually mild, but out of proportion
(mPAP ge40 mm Hg) in 12%. Patients with PH had significantly higher frequencies of the
5HTT-L-allele (52%) compared to individuals without PH (36%), and LL homozygote patients had
more severe PH. In patients with out-of-proportion PH, the L-allelic frequency was even 75%. We
found no association of 5HTR2a and eNOS polymorphism with PH in COPD. Conclusions: In this
COPD cohort we confirm that PH is frequent and usually mild, but out of proportion in a subgroup. We
found a significant association of the L-allelic variant of 5HTT with PH overall and especially in
out-of-proportion PH. These findings may point towards a role of the serotonin system in COPD-PH and
warrant further studies.
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pared to individuals without PH (36%), and LL homozygote 
patients had more severe PH. In patients with out-of-propor-
tion PH, the L-allelic frequency was even 75%. We found no 
association of 5HTR2a and eNOS polymorphism with PH in 
COPD.  Conclusions: In this COPD cohort we confirm that PH 
is frequent and usually mild, but out of proportion in a sub-
group. We found a significant association of the L-allelic 
 variant of 5HTT with PH overall and especially in out-of-pro-
portion PH. These findings may point towards a role of the 
serotonin system in COPD-PH and warrant further studies. 
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Chronic obstructive pulmonary disease (COPD) is 
one of the leading causes of morbidity in the Western 
world, mainly due to cigarette smoking. COPD leads to 
pulmonary hypertension (PH) in some subjects, but not 
in others  [1] . The development of PH in COPD has been 
mainly attributed to alveolar hypoxia, which leads to 
 pulmonary vasoconstriction, vessel remodeling and in-
creased pulmonary vascular resistance  [1] . Long-term 
oxygen therapy improves the prognosis of patients with 
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 Abstract 
 Background: Pulmonary hypertension (PH) is prognosti-
cally important in chronic obstructive pulmonary disease 
(COPD). Since PH only weakly correlates with hypoxemia, 
other factors must play a role.  Objective: To investigate 
whether polymorphisms of the serotonin transporter (5HTT), 
serotonin-2a receptor (5HTR2a) and endothelial nitric oxide 
synthetase (eNOS) are related to PH in COPD.  Methods: In 59 
COPD patients who underwent right heart catheterization, 
6-min walking distance, NYHA functional class, pulmonary 
function tests, blood gases and 5HTT, 5HTR2a and eNOS 
(4ab and T298C) polymorphisms were determined.  Results: 
Forty-nine COPD patients in NYHA functional class III–IV 
were  included. Ten were excluded due to comorbid causes 
of PH (mainly chronic thromboembolic). PH (mPAP  6 25 mm 
Hg) was present in 55% and usually mild, but out of propor-
tion (mPAP  6 40 mm Hg) in 12%. Patients with PH had sig-
nificantly higher frequencies of the 5HTT-L-allele (52%) com-
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COPD and stabilizes pulmonary artery pressure, and PH 
is the strongest prognostic factor for COPD patients un-
der long-term oxygen therapy, independent of the severi-
ties of airflow limitation or hypoxemia  [2] . But not every 
hypoxemic COPD patient develops PH and the degree of 
PH only weakly correlates with hypoxemia; therefore, 
other predisposing factors must be postulated, most 
probably genetic ones. In most COPD patients, PH is 
mild  [3, 4] , however, a subgroup develops severe and rap-
idly progressive PH resembling other forms of vasopro-
liferative pulmonary vessel disease, such as idiopathic 
pulmonary arterial hypertension (PAH)  [5, 6] . Recogni-
tion of a genetic susceptibility to PH in COPD patients 
would have relevant implications for the pathogenetic 
understanding, and potentially early diagnosis and treat-
ment. Important factors contributing to the pathogenesis 
of PH in various diseases are nitric oxide (NO), serotonin, 
endothelin and prostaglandins.
 Polymorphism of the serotonin transporter (5HTT) 
determined the severity of PH in hypoxemic French and 
British patients with COPD  [7] . However, this association 
could not be found in idiopathic or familial PAH  [8] . Se-
rotonin leads to pulmonary vasoconstriction via its 2a 
and b receptors (5HTR2a and b). The T102C polymor-
phism of 5HTR2a  has been associated with arterial hy-
pertension, myocardial infarction and psychiatric disor-
ders  [9, 10] , but has not been investigated in PH. NO plays 
a key role in systemic and pulmonary endothelial dys-
function  [11] . Polymorphism in the endothelial NO syn-
thetase (eNOS) has been associated with the development 
of arteriosclerosis and high altitude pulmonary edema in 
Japanese and Indian populations  [12, 13] . However, eNOS 
polymorphisms were not related to pulmonary artery 
pressures at altitude in Caucasians  [14] .
 The aim of the present study was to investigate the as-
sociation of 5HTT, 5HTR2a and eNOS polymorphisms 
with PH confirmed by right heart catheterization (RHC) 
in COPD patients.
 Material and Methods 
 Study Subjects 
 Outpatients with COPD diagnosed according to the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) guide-
lines  [15–17] who had RHC and pulmonary function testing 
(PFT) within 2 weeks were asked to participate upon written in-
formed consent. Patients were scheduled for RHC according to 
their treating physicians’ judgment (mostly physicians not in-
volved in the study inclusion) mainly because they had severe 
exertional dyspnea (often more than expected from their PFT) 
and/or before lung volume reduction surgery. The study was ap-
proved by the local ethics review board. Fifty-nine COPD pa-
tients (25 females) at a mean age of 68  8 8 years were assessed. 
Ten patients were excluded because a thorough investigation re-
vealed other reasons for PH: 6 patients had chronic thromboem-
bolic PH confirmed by pulmonary angiography, 3 patients had 
postcapillary PH due to left heart disease and 1 patient was diag-
nosed with scleroderma. Thus, data from 49 COPD patients were 
analyzed.
 Study Assessments 
 Patients willing to participate had their blood lymphocytes 
genetically analyzed. Demographics including age, sex, height, 
weight, body mass index, smoking history, drug use, NYHA class 
and 6-min walking distance were obtained, all within 2 weeks of 
RHC and PFT. Swan-Ganz catheters were placed by standard 
techniques and cardiac output was assessed by thermodilution 
(Baxter/Edwards, Deerfield, Ill., USA). Hemodynamic data from 
RHC (mean pulmonary artery pressure, mPAP; cardiac index; 
pulmonary vascular resistance), arterial and mixed venous blood 
analysis (oxygen and carbon dioxide pressures and saturation), 
and data from PFT (forced expiratory volume in 1 s; forced vital 
capacity; total lung capacity; residual volume; single breath trans-
fer factor for carbon monoxide; all given as percent predicted) 
were noted. We defined mPAP according to the WHO as  6 25 
mm Hg  [18] and out-of-proportion PH in COPD as mPAP  1 40 
mm Hg  [19] .
 Genetic Analysis 
 EDTA-supplemented blood samples were extracted with the 
QIAamp  DNA Mini Kit (Qiagen AG, Basel, Switzerland). Prim-
ers were designed with the OLIGO 4.0 software (Medprobe, Oslo, 
Norway) and purchased from Microsynth (Balgach, Switzer-
land).
 For detection of the Glu298Asp polymorphism in  eNOS , a 25-
  l tetraprimer PCR reaction was developed using the Amplitaq 
Gold TM System (Perkin-Elmer Corp., Hünenberg, Switzerland); 
0.1   M of primers NOSU6749 (5  -AGGGGAGCCTCGGTGAG-
ATAAAG-3  ) and NOSL7115 (5  -GCAGGCCCTTCTTGAGA-
GG-3  ), as well as 0.14   M of primers NOSU6986G (5  -TGCA-
GGCCCCAGATGAG-3  ) and NOSL7002T (5  -AAGGAAGAG-
TTCTGGGGGA-3  ) were added to the standard amplification 
mixture with 100 ng genomic DNA and the following cycling pa-
rameters were used: 10 min at 94 ° C, 10 cycles (first set) of 94 ° C 
for 30 s, 60 ° C for 30 s, 72 ° C for 60 s, 25 cycles (second set) of 94 ° C 
for 30 s, 53 ° C for 30 s, 72 ° C for 60 s, and a final extension of 7 min 
at 72 ° C  [20, 21] .
 Genotyping of the 27-bp repeat in intron 4 of the  eNOS gene 
(eNOS4a/b) was performed according to Wang et al.  [22] with 
minor modifications. The allele with 4 repeats was designated 4a 
and the longer allele with 5 repeats was designated 4b. The 44-bp 
insertion/deletion polymorphism in  5HTT was analyzed using 
0.5   M of primers 5HTT U (5  -CTC TGA ATG CCA GCA CCT 
AAC-3  ) and 5HTT L (5  -GGA TTC TGG TGC CAC CTA GAC-
3  ) as well as the Expand Long Template Kit from Roche Molecu-
lar Biochemicals (Rotkreuz, Switzerland). PCR resulted in a long 
amplification product of 457 bp and in a short amplification
product of 414 bp for the 2 alleles which were separated on aga-
rose gels.
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 For detection of the T102C polymorphism in the  HTR2A gene, 
a LightCycler assay was developed. Four oligonucleotides were 
added to the LightCycler DNA Master Hybridization Probes mix-
ture (Roche Molecular Biochemicals) at the following final con-
centrations: 0.5   M of HTR2A U135 (5  -CTG GCT TAG ACA 
TGG ATA TT-3  ) and HTR2A L336 (5  -ATG AAG TAA GGA 
GAG ACA CG-3  ), 0.4   M of Anchor T102C (5  -LCRed640-TTA 
CTG TAG AGC CTG GTG TCA TCA TTT-ph-3  ) and 0.2   M of 
Sensor T102C (5  -GTT AGC TTC TCC AGA GTT AAA GTC-FL-
3  ). The final magnesium concentration was 2 mmol/l, and 100 
ng DNA were added in a total volume of 20   l. The following tem-
perature protocol was applied: 95 ° C for 45 s, followed by 50 cycles 
of 95 ° C for 0 s, 58 ° C for 10 s, and 72 ° C for 9 s with a ramping rate 
of 20 ° C/s. Melting curve analysis was performed from 40 ° C to 
85 ° C at a linear rate of 0.1 ° C/s  [23] .
 Statistical Analysis 
 Results are expressed as means  8 SD. The Mann-Whitney U 
test and analysis of variance were used to compare means and 
Fisher’s exact test was applied to compare frequencies between 
groups. Differences showing p  ! 0.05 were considered statisti-
cally significant. Statistical analysis was performed using SPSS 
version 15.0 software package.
 Results 
 Patients’ Characteristics and Clinical Presentation 
 The baseline characteristics of the 49 patients included 
are shown in  table 1 . All patients were in NYHA classes 
III and IV and were severely exercise limited (mean 6-
min walking distance 298  8 125 m). COPD severity ac-
cording to GOLD varied, all but 3 were moderately to 
severely affected. Most patients had a history of cigarette 
smoking. PH was present in 27 (55%) of the patients. RHC 
was performed during a stable condition without any 
signs for COPD exacerbation and on room air. Overall, 
PH was usually mild, however, 6 (12%) patients had out-
of-proportion PH ( fig. 1 ). Patients with PH had less severe 
airway obstruction and lung hyperinflation compared to 
patients without PH ( table 2 ). We found a weak correla-
tion between the degrees of hypoxemia and PH ( fig. 2 ), 
but an even weaker inverse correlation between the se-
verities of airway obstruction and PH.
Table 1. Patient characteristics
Numbers
Total number of patients 49 (100)
Females/males 18/31 (37/63)
Age, years 6888
Body mass index 2484
Smokers 44 (90)
Current/past 5/39 (11/79)
Mean pack years smoked 52830
NYHA functional class III-IV 21/28 (43/57)
6-min walking distance, m 2988125
COPD severity by GOLD stage I/II/III/IV 3/12/20/14 
(6/25/41/28)
Pulmonary function tests1
FEV1, % predicted 41821
FVC, % predicted 74825
FEV1/FVC ratio 0.4880.12
Total lung capacity, % predicted 120825
Residual volume, % predicted 196874
Carbon monoxide diffusion capacity
% predicted 42822
Pulmonary hemodynamics (invasive)
mPAP, mm Hg 28811
Cardiac index, l/min/m2 2.580.6
Pulmonary vascular resistance, dynsecm–5 3788222
Right atrial pressure, mm Hg 6.585
Pulmonary artery occlusion pressure, mm Hg 1084
Blood gas analysis
Arterial oxygen saturation, % 9086
Arterial oxygen partial pressure, kPa 7.981
Arterial carbon dioxide partial pressure, kPa 5.480.8
Mixed venous oxygen saturation, % 6488
Figures in parentheses are percentages. FEV1 = Forced expira-
tory volume in 1 s; FVC = forced vital capacity.
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 Fig. 1. Percent of COPD patients with mPAP above different 
thresholds (n = 49). 
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Table 2. Characteristics of COPD patients with and without PH (mPAP ≥25 mm Hg)
Without PH With PH
Total number of patients 22 (45) 27 (55)
Females/males 5/17 (23/77) 13/14 (48/52)
Age, years 6687 7088
Body mass index 2484 2485
Smokers 21 (95) 22 (81)
Current/past 1/20 (5/95) 4/18 (18/78)
Mean pack years smoked 55828 49833
NYHA functional class III /IV 11/11 (50/50) 10/17 (37/63)
6-minute walking distance, m 2688129 3238118
COPD severity by GOLD stage I/II/III/IV 0/2/11/9 (0/9/50/41) 3/10/9/5 (11/40/33/16)
Pulmonary function tests1
FEV1, % predicted 30811 51823**
FVC, % predicted 66822 81825*
FEV1/FVC ratio 0.4680.12 0.5080.11
Total lung capacity, % predicted 128823 113824*
Residual volume, % predicted 228863 167871**
Carbon monoxide diffusion capacity, % predicted 39815 44827
Pulmonary hemodynamics
mPAP, mm Hg 1984 35810**
Cardiac index, l/min/m2 2.580.5 2.580.7
Pulmonary vascular resistance, dynsecm–5 238898 4738223**
Right atrial pressure, mm Hg 584 885
Pulmonary artery occlusion pressure, mm Hg 984 1084
Blood gas analysis
Arterial oxygen saturation, % 9284 8887
Arterial oxygen partial pressure, kPa 8.181.0 7.681.1
Arterial carbon dioxide partial pressure, kPa 5.480.8 5.480.8
Mixed venous oxygen saturation, % 6685 6389
Data given as numbers (%) or means 8 SD. * p < 0.05; ** p < 0.01.
1 Normal values obtained from the European Society of Coal and Steel.
Table 3. Frequencies of the serotonin transporter polymorphisms in COPD patients (overall and by the pres-
ence of PH)
COPD patients Genotypes Allele
frequencies, %
SS SL LL S L
Overall (n = 49) 13 (27) 28 (57) 8 (16) 63 37
No PH (n = 22) 8 (36) 12 (55) 2 (9) 64 36
With PH (n = 27) 5 (19) 16 (59) 6 (22) 48 52*
Out-of-proportion PH (n = 6) 0 3 (50) 3 (50) 25 75**
Figures in parentheses are percentages. * p < 0.05 for COPD with versus without PH; ** p < 0.05 for out-of-
proportion PH ( defined as mPAP >40 mm Hg) versus without PH and/or all  others.
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 Fig. 2. mPAP plotted against arterial oxygen pressure (PaO 2 ). 
Table 4. Frequencies of the tested serotonin-2a receptor and NO synthetase polymorphisms in COPD patients 
(overall and by the presence of PH)




5HTR2a TT TC CC T C
Overall (n = 49) 8 (16) 30 (61) 11 (23) 44 56
No PH (n = 22) 5 (23) 12 (54) 5 (23) 50 50
With PH (n = 27) 3 (11) 18 (67) 6 (22) 48 52
eNOS4a/b bb ab aa b a
Overall (n = 49) 31 (63) 17 (35) 1 (2) 84 16
No PH (n = 22) 14 (64) 8 (36) 0 82 18
With PH (n = 27) 17 (63) 9 (33) 1 (4) 80 20
eNOS298 Glu/Glu Glu/Asp Asp/Asp Glu Asp
Overall (n = 49) 25 (51) 22 (45) 2 (4) 78 22
No PH (n = 22) 11 (50) 9 (41) 2 (9) 70 30
With PH (n = 27) 14 (52) 13 (48) 0 76 24
Figures in parentheses are percentages.





















 Fig. 3. mPAP (mm Hg) by 5HTT allelic variants. 
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 Genetic Analysis 
 Frequencies of the 5HTT, 5HTR2a and eNOS (4a/b 
and 298) genotypes are shown in  table 3 and  4 for all 
COPD patients separated by the presence of PH. COPD 
patients with PH were significantly more likely to carry 
the LL genotypes of the 5HTT gene compared to COPD 
without PH (p = 0.03). Three of the 6 patients with PH 
 1 40 mm Hg were homozygote for the LL variant and 3 
heterozygote, the allelic frequency of the L variant of the 
5HTT was herewith highly overrepresented in this sub-
set (p  ! 0.001;  table 3 ). Overall, patients with the L-allelic 
variant of the 5HTT tended to have higher pulmonary 
artery pressure ( fig. 3 ) and vascular resistance. With 
mean mPAPs of 33  8 6, 29  8 2 and 23  8 2 mm Hg (95% 
confidence intervals 19–26, 25–33 and 21–47 mm Hg, re-
spectively) for the LL, LS and SS genotypes, respectively, 
our results were in close accordance with the study of Ed-
dahibi et al.  [7] , which found mPAPs of 33  8 6, 29  8 2 
and 23  8 2 mm Hg, respectively, in their French collec-
tive (n = 67). However, our study did not reach statistical 
significance due to the smaller sample size (n = 49). Ret-
rospective power calculation revealed that for signifi-
cance we would have needed a sample size of 48 (actually 
41) and 30 (actually 21) to detect the presently found 
mPAP differences of 6 and 12 mm Hg, respectively, be-
tween the SS and LS and SS and LL allelic groups, respec-
tively. If looking at the mPAP difference between the SS 
allele carriers versus carriers of any L allele (30  8 5 mm 
Hg), the difference just failed statistical significance (p = 
0.057). Conversely, patients homozygote for the S-allelic 
variant had significantly more severe airway obstruction 
compared with patients carrying the L allele (p = 0.04). 
There were no other significant differences of any inves-
tigated allele variant between COPD patients with and 
without PH, and none of the measured parameters dif-
fered according to any investigated genotype.
 Discussion 
 In this study we confirm that even in a selected COPD 
collective scheduled for RHC, PH is usually relatively 
mild, only weakly related to hypoxemia and not related 
to the degree of airway obstruction  [5] . However, similar 
to others we found that a subgroup of COPD patients 
(12%) presents with out-of-proportion elevated pulmo-
nary artery pressure ( 1 40 mm Hg) similar to the features 
seen in (idiopathic) PAH  [1, 5, 6, 24] . In this group, we 
found a marked overrepresentation of the 5HTT long al-
lelic variant (L). Hence, our data corroborate the findings 
of Eddahibi et al.  [7] that the homozygote LL genotype of 
5HTT is associated with PH in COPD patients, suggest-
ing a role of the serotonin system in the pathogenesis of 
PH in COPD.
 The pathogenesis behind PH in COPD is incomplete-
ly understood. However, particularly in the development 
of out-of-proportion PH, genetic variants may play a role. 
Germline mutations in the bone morphogenetic protein 
receptor 2 play an important pathogenetic role in familial 
and sporadic, but not in other forms of PAH, such as 
those associated with HIV infection or scleroderma  [25, 
26] . However, bone morphogenetic protein receptor 2 
mutations have not been studied in COPD-PH so far. Ed-
dahibi et al.  [7] showed an association of the long allelic 
variant of the 5HTT with the degree of PH in hypoxic 
COPD patients. Consistently, we found an increased fre-
quency of the L allele in COPD patients with PH in our 
cohort. Strikingly, the L-allelic variant was markedly 
overrepresented in the 6 patients with out-of-proportion 
PH. In accordance, patients with the L-allelic variant had 
higher mPAPs and PVRs compared to patients with the 
S variant ( table 3 ;  fig. 3 ). These findings support a patho-
genetic role of the serotonin system in the development 
of PH in COPD and indicate the need for further studies 
in this field. 5HTT has been shown to be a key determi-
nator of pulmonary vessel remodeling by mediating pro-
liferation of pulmonary artery smooth muscle cells, di-
rectly related to 5HTT gene expression  [27–30] . Cells ho-
mozygous for the L-allelic variant have been shown to 
express 2-fold more 5HTT RNA compared to cells carry-
ing the S-allelic variant. This difference was even more 
pronounced under hypoxic conditions. This may explain 
why the 5HTT polymorphism seems only related to PH 
in COPD, a disorder closely associated with hypoxemia, 
while there does not seem to be a relation with other 
forms of PH  [8, 31] . In line with a previous study  [7] , we 
also found more severe airway obstruction in patients ho-
mozygous for the S-allelic variant. One speculative expla-
nation for this difference might be that patients with the 
L-allelic variant become symptomatic due to higher pul-
monary artery pressure earlier in the disease, when they 
have less airflow limitation. Given the prognostic impact 
of PH in COPD, early identification and especially fur-
ther studies assessing therapeutic opportunities for PH in 
COPD are mandatory. One approach could be to investi-
gate the effect of 5HTT inhibitors on PH in selected 
COPD patients, as they have been shown to inhibit the in 
vitro proliferative response of smooth muscle cells when 
given orally to experimental animals exposed to hypoxia 
 [29, 32] .
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 Agonists of the 5HT2 receptors, such as fenfluramine, 
are associated with an increased risk for PH  [33] , and 
5HTR2 receptor antagonists are currently investigated as 
treatment options in PH  [34, 35] .
 Although usually mild, PH is the most important ter-
minator of outcome in COPD  [36] . It has been shown that 
PH in COPD is only moderately linked to hypoxemia and 
even less to the degree of airflow obstruction. Therefore, 
genetics, environmental and comorbid factors must play 
a pathogenetic role  [3, 4, 36, 37] . Severe PH in COPD is 
rare and may indicate a clinically and pathogenetically 
distinct disease  [6, 18] . In our collective, mild PH was 
present in up to 84% of patients considering a threshold 
mPAP  6 20 mm Hg (as widely used in the respiratory lit-
erature)  [3, 4, 38] , and in 55% if defined by the WHO 
(mPAP  6 25 mm Hg). This is in line with previously pub-
lished articles  [18, 39] . However, in analogy to previous 
reports  [18] , severe PH (mPAP  1 40 mm Hg) was found in 
12% of the present COPD cohort. Whether this out-of-
proportion PH in COPD reflects a pathogenetically dis-
tinct COPD subset and whether this subset might be 
amenable to specific PH therapy warrants further stud-
ies. It is also important to mention that other reasons for 
PH may be found in COPD patients. In our study we ex-
cluded 10 (27%) out of totally 37 COPD patients with PH 
for comorbid reasons. Many of them suffered from chron-
ic thromboembolic PH, a potentially surgically accessible 
disease  [40] , others had diastolic left heart dysfunction 
and 1 patient was diagnosed with scleroderma. The diag-
nosis of other PH-associated comorbid conditions in 
COPD patients is important, as specific therapies for 
some PH classes may considerably improve the patients’ 
quality of life and prognosis.
 The development of PH in COPD is mainly attributed 
to alveolar hypoxia  [4] . In line with previous studies, we 
found a mild association between hypoxemia and PH se-
verity  [7, 18] . As for the degree of airway obstruction, the 
association with PH severity was even weakly inverse in 
our collective  [7] . This may partly be explained by selec-
tion, as we only included COPD patients scheduled for 
RHC and therefore possibly had more patients with out-
of-proportion PH, a subset possibly mimicking PAH 
 [18] .
 The present study has several limitations. First, we 
studied a selected COPD population scheduled for RHC. 
It must therefore be assumed that PH might be overrep-
resented in this collective due to selection bias. It could 
thus be that the clinical and genetic differential charac-
teristics of COPD patients would be different in a more 
general COPD collective with milder disease. However, 
as specific therapy for PH in COPD is currently lacking 
and as there is no evidence-based study demonstrating 
the clinical value of RHC in advanced COPD, it would be 
ethically difficult to search for PH using RHC in a gen-
eral COPD population outside a proper study protocol. A 
second limitation is the relatively small sample size. How-
ever, for the above mentioned reasons, RHC is not per-
formed very often in COPD patients. Third, we herein 
investigated only some genetic variants of the serotonin 
and NO system. It could well be true that other, herein 
not accounted, genetic variants play a role in COPD-as-
sociated PH.
 In summary, our study confirms previous results that 
the long allelic variant of the serotonin transporter is as-
sociated with PH in COPD, especially in those with out-
of-proportion pulmonary artery pressures. Our data sup-
port a possible role of the serotonin system in the patho-
genesis of COPD-associated PH and will help to direct 
future research in the field.
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